Data Insights

Narazaciclib by Traws Pharma for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

Narazaciclib is under clinical development by Traws Pharma and currently in Phase I for Human Epidermal Growth Factor Receptor 2...

Likelihood of Approval and Phase Transition Success Rate Model - Narazaciclib in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

Narazaciclib by Traws Pharma for Colorectal Cancer: Likelihood of Approval

Narazaciclib is under clinical development by Traws Pharma and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Narazaciclib in Colorectal Cancer

Data Insights

Narazaciclib by Traws Pharma for Endometrial Cancer: Likelihood of Approval

Narazaciclib is under clinical development by Traws Pharma and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Narazaciclib in Endometrial Cancer

Data Insights

Viroksavir by Traws Pharma for Pandemic Influenza: Likelihood of Approval

Viroksavir is under clinical development by Traws Pharma and currently in Phase I for Pandemic Influenza. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Viroksavir in Pandemic Influenza

Data Insights

Viroksavir by Traws Pharma for Haemophilus influenzae Type A Infections: Likelihood of Approval

Viroksavir is under clinical development by Traws Pharma and currently in Phase I for Haemophilus influenzae Type A Infections. According...

Likelihood of Approval and Phase Transition Success Rate Model - Viroksavir in Haemophilus influenzae Type A Infections

Data Insights

Viroksavir by Traws Pharma for Haemophilus influenzae Type B Infections: Likelihood of Approval

Viroksavir is under clinical development by Traws Pharma and currently in Phase I for Haemophilus influenzae Type B Infections. According...

Likelihood of Approval and Phase Transition Success Rate Model - Viroksavir in Haemophilus influenzae Type B Infections

Data Insights

Viroksavir by Traws Pharma for Seasonal Influenza: Likelihood of Approval

Viroksavir is under clinical development by Traws Pharma and currently in Phase I for Seasonal Influenza. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Viroksavir in Seasonal Influenza

Data Insights

Rigosertib sodium by Traws Pharma for Non-Small Cell Lung Cancer: Likelihood of Approval

Rigosertib sodium is under clinical development by Traws Pharma and currently in Phase II for Non-Small Cell Lung Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Rigosertib Sodium in Non-Small Cell Lung Cancer

Data Insights

Rigosertib sodium by Traws Pharma for Lung Adenocarcinoma: Likelihood of Approval

Rigosertib sodium is under clinical development by Traws Pharma and currently in Phase II for Lung Adenocarcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Rigosertib Sodium in Lung Adenocarcinoma

Data Insights

Rigosertib sodium by Traws Pharma for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

Rigosertib sodium is under clinical development by Traws Pharma and currently in Phase II for Squamous Non-Small Cell Lung Cancer....

Likelihood of Approval and Phase Transition Success Rate Model - Rigosertib Sodium in Squamous Non-Small Cell Lung Cancer

Data Insights

Rigosertib sodium by Traws Pharma for Squamous Cell Carcinoma: Likelihood of Approval

Rigosertib sodium is under clinical development by Traws Pharma and currently in Phase II for Squamous Cell Carcinoma. According to...

Data Insights

Rigosertib sodium by Traws Pharma for Epidermolysis Bullosa: Likelihood of Approval

Rigosertib sodium is under clinical development by Traws Pharma and currently in Phase II for Epidermolysis Bullosa. According to GlobalData,...